Abstracts tagged "prostaglandins"

Abstract Number: 0704 • ACR Convergence 2025
Human Pharmacokinetics of Inhaled Liposomal Iloprost Support a Dosing Regimen for Treating Systemic Sclerosis- Related Digital Ulcer
Pei Kan, Ko-Chieh Chen and Shin-Shin Chuang, Pharmosa Biopharm Inc, Taipei, Taiwan (Republic of China)
Background/Purpose: Iloprost is recommended and widely used in Europe for treating systemic sclerosis (SSc)-related Raynaud Phenomena (RP) and Digital Ulcer (DU). EULAR recommendation suggests continuous…
Abstract Number: 596 • 2019 ACR/ARP Annual Meeting
Prostaglandin Receptor EP4 Drives Pathogenic Th17 Cell Development in Ankylosing Spondylitis and Is a New Marker of Disease Activity
Anja Meyer¹, Charlotte Klasen ¹, Pauline Wittekind ¹, Iris Waqué ¹, Schafiq Nabhani ¹ and David Kofler ¹, ¹University of Cologne, Cologne, Germany
Background/Purpose: Th17 cells are involved in the pathogenesis of ankylosing spondylitis (AS). However, the mechanism underlying enhanced Th17 cell accumulation in AS remains unknown. The…
Abstract Number: 415 • 2012 ACR/ARHP Annual Meeting
Hypoxia-Induced Endogenous Prostaglandin E2 Negatively Regulates Hypoxia-Enhanced Aberrant Overgrowth of Rheumatoid Synovial Tissue
Hirofumi Mitomi¹, Hidehiro Yamada¹, Toshiko Nozaki Shibata¹, Hiroshi Ito¹, Yoshioki Yamasaki², So Nomoto³, Atsushi Kusaba⁴, Hiroki Yamashita⁴ and Shoichi Ozaki¹, ¹Internal Medicine, St. Marianna University, Kawasaki, Japan, ²Medicine, St. Marianna University, Kawasaki, Japan, ³Department of Orthopedic Surgery and Rheumatology, Saiseikai Yokohamashi Tobu Hospital, Yokohama, Japan, ⁴Institute of Rheumatology, Ebina General Hospital, Ebina, Japan
Background/Purpose: During isometric exercise, the synovial joint tissue is prone to hypoxia, which is further enhanced in the presence of synovial inflammation. Hypoxia is also…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].